LES Royalty Rates and Deal Terms Surveys
Licensing Executives Society (U.S.A. and Canada) (LES) launched a broad-reaching Royalty Rates and Deal Terms survey initiative to address the elusive gaps in industry-specific deals and trends. Available for FREE to members, the results of past surveys covering Life Sciences, High Technology, and Physical Sciences Royalty Rates and Deal Terms. Member Rate: FREE
Non-Member Rate: $795 each The Licensing Executives Society USA & Canada, along with the Licensing Executives Society International, is updating its High Tech Sector Global Royalty Rates & Deal Terms Survey for deals entered into from November 2021 through the current date. We need your participation to make the survey useful. On average, the survey takes 5 mins for each complete input. Before you start the survey, we suggest that you have a copy of your license agreement handy in order to respond.
If you didn't receive an email from Vault Consulting to participate in the survey, please click on this link that will take you to a survey opt-in page: Survey Opt-in Form or copy and paste the following URL into your browser: https://vaultconsulting.qualtrics.com/jfe/form/SV_8bTFedxCShNSAxU 2024 Life Sciences Royalty Rates & Deal Terms Survey is available!
|
2021 Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2021 Royalty Rate & Deal Terms Executive Summary
PDF (194.16 KB)
|
Administration
|
8/1/2023
|
|
2017 Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2014 Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2014 Royalty Rate & Deal Terms Executive Summary
PDF (137.58 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
|
The 2014 High Tech Deal Terms & Royalty Rate Survey Report is the second comprehensive Deal Terms & Royalty Rate Survey undertaken for the High Tech Sector (HTS) of LES. The survey addressed major fields within the HTS, including aerospace, software, clean technology, communications, medical devices, semiconductors, consumer products, electronics, and computers. The sample size included 94 participants coming from various sizes and types of organizations. Much has changed in the world of patents and IP licensing since the last LES licensing survey in 2011, and this report analyzes the combined data of the 2011 and 2014 surveys, and explains trends in a variety of matters, such as trends about how technology types are affected in the licensing market.
|
|
2011 Royalty Rate & Deal Terms Survey Link
|
Administration
|
8/25/2025
|
|
2011 Royalty Rate & Deal Terms Executive Summary
PDF (218.25 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
Survey Highlights
-The Survey received responses from 52 companies for the period from 2008 through 2011, with a total of 228 complete deals being submitted.
-The following major high technology fields were reported: aerospace, software, clean technology, communication, semiconductor, consumer products and electronics.
-86% of respondents were licensors, with more than half of them entering the deal for monetary gain in addition to a strategic relationship.
|
|
2024 Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2024 Royalty Rate & Deal Terms Executive Summary
PDF (1.44 MB)
|
Administration
|
9/23/2025
|
|
2021 Royalty Rate & Deal Terms Survey Link
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
LES Life Sciences Sector Royalty Rates & Deal Terms Survey
The survey went out to approximately 2,469 LES members and 17,431 non-members, resulting in a higher response rate of 6.3% compared with 5% in 2014. A total of 155 specific intellectual property deals transacted between 2014 and 2017 were analyzed. Deals of all types were submitted including sales and licenses; out-licenses and in-licenses; lump sum and running royalty; and flat and tiered loyalty.
"The valuable data we've gathered through the LES Life Sciences Sector Royalty Rates & Deal Terms Survey is not available from other public and commercial sources and reveals much more insight into the dynamics of the licensing market, given that we have the unique ability to analyze and compare the transaction-level data going back to 2008," said Jack Lu, Ph.D., CFA, LES Senior Vice President of Economic Analysis and Survey, and a Partner and Chief Economist of IPMAP, LLC
|
|
2021 Royalty Rate & Deal Terms Executive Summary
PDF (588.18 KB)
|
Administration
|
9/23/2025
|
|
2018 Royalty Rate & Deal Terms Survey Link
|
Administration
|
7/31/2023
|
|
2018 Royalty Rate & Deal Terms Executive Summary
PDF (730.16 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
2018 Survey Highlights
A total of 101 completed surveys were incorporated into the final Global Life Sciences Survey Report.
Of those who responded, 24% were from pharmaceutical companies, 4% were from biotech companies, 21% were from academic institutions, 8% were from government, and 45% were from other organizations.
Survey respondents represented 10 of the 31 Licensing Executives Society International (LESI) Societies
|
|
2016 Royalty Rate & Deal Terms Survey Link
|
Administration
|
7/31/2023
|
|
2016 Royalty Rate & Deal Terms Executive Summary
PDF (581.31 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
2016 Survey Highlights
A total of 117 completed surveys were incorporated into the final Global Life Sciences Survey Report.
Of those who responded, 19% were from pharmaceutical companies, 12% were from biotech companies, 22% were from academic institutions, 11% were from government, and 36% were from other organizations.
Survey respondents represented 8 of the 33 Licensing Executives Society International (LESI) Societies
|
|
2014 Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2014 Royalty Rate & Deal Terms Executive Summary
PDF (129.12 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
2014 Survey Highlights
A total of 128 completed surveys were incorporated into the final Global Life Sciences Survey Report.
Of those who responded, 16% were from pharmaceutical companies, 19% were from biotech companies, 20% were from academic institutions, 7% were from government, and 38% were from other organizations.
Approximately 64% of the deals were considered “Global” in scope.
|
|
2009 Royalty Rate & Deal Terms Executive Summary
PDF (455.72 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
Survey Highlights
A total of 184 completed surveys were incorporated into the final Global BioPharma Survey Report with over 40% of the reported deals from outside North America. This is a 20% increase in response from 2008.
Of those who responded, 39% were from pharmaceutical companies, 23% were from biotech companies, 12% were from academic institutions, 6% were from government, and 20% were from other organizations.
The survey report provides a detailed analysis on fixed royalties, tiered royalties, deal terms, valuation methods, and therapeutic areas.
Over 80% of the deals submitted had licenses that included the United States and close to 63% of licenses were considered “Global” in scope. Sixty-one percent of the deals were reported by the licensors and 82% of the deals were categorized as exclusive.
|
|
2008 Royalty Rate & Deal Terms Executive Summary
PDF (449.12 KB)
[ more ]
[ hide ]
|
Administration
|
9/23/2025
|
Survey Highlights
Over 150 deals analyzed, involving pharmaceutical companies (28%), biotechnology companies (26%), and academic Institutions (35%).
120 deals completed in 2006 or 2007
Key Deal Terms
Small Molecule compounds were included in more than 50% of all deals submitted
88% of deals were exclusive
54% of deals included a fixed royalty; 33% included tiered royalty rates
80% included an upfront payment
90% of deals included U.S. rights; 70% were worldwide
57% of products covered have estimated peak sales of less than $100M
|
|
2022 Phy Sciences Royalty Rate & Deal Terms Survey Link
|
Administration
|
9/23/2025
|
|
2010 CEEM Royalty Rate and Deal Terms Survey Link
|
Administration
|
7/31/2023
|
|
2010 CEEM Executive Summary
PDF (74.92 KB)
[ more ]
[ hide ]
|
Administration
|
2/16/2016
|
2010 Survey Highlights
Survey participation included academic institutions (34%), operating companies that ranged from big energy to start-up (39%), lawyers (16%), and other licensing organizations (11%).
Approximately 70% of the deals collected contained flat running royalties and most deals were entered by the licensor. About 75% of the deals were executed during 2008 or 2009 and 80% of the deals came from the chemicals and energy sectors.
Of those reported, approximately 40% of the deals estimated peak annual sales of less than $50 million, most deals involved commercialized or soon to be commercialized products/technologies and a majority of the deals were exclusive.
|
|
Print Page
